Triple‐negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), is the most aggressive subtype accounting for 10–20% of all breast cancer cases.[1] It has a poor prognosis and a high risk of recurrence. Here, ESR1 is linked to breast carcinoma.